General characteristics and features of the use of nonsteroidal anti-inflammatory drugs in the treatment of dorsopathies in clinical practice (literature review)

Back pain ranks first among all non-communicable diseases in terms of the number of years of life lost due to poor health. At the same time, the choice of tactics for the treatment of dorsopathies presents certain difficulties, in particular, the choice of a nonsteroidal anti-inflammatory drug (NSAID), which depends on a number of factors. NSAIDs are effectively used in the treatment of musculoskeletal pain, but they have side effects, which determines the individual characteristics of their use. The article presents an overview of scientific data published in the sources MEDLINE, PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Clinical Trials.gov, services for the exchange of research information on the clinical practice of NSAID use. The general characteristics and side effects of NSAIDs in clinical practice are analyzed in order to choose an effective and safe trajectory of their use in the treatment of dorsopathies. In the acute period of dorsopathy, the therapeutic effect should be aimed primarily at reducing pain. At the same time, the use of NSAIDs is necessary and justified, should include a detailed assessment of side effects, duration of use, alternative trajectories of drug and non-drug treatment. Numerous side effects of NSAIDs from the gastrointestinal tract, liver, cardiovascular system, allergic reactions, congenital anomalies in the fetus when using NSAIDs during pregnancy and other undesirable consequences, make it necessary to take the maximum possible measures to minimize adverse reactions and long-term undesirable consequences for the patient. Combined therapeutic effects, including, along with the use of NSAIDs, physiotherapy, physical therapy, massage, reflexotherapy, optimization of motor activity, optimization of posture under static loads, the use of cognitive behavioral therapy methods, is optimal from the standpoint of risk stratification and the expected clinical effect in patients with dorsopathy.

1. Podchufarova E.V. Acute and chronic lumbosacral pain: Topical problems. Neurology, Neuropsychiatry, Psychosomatics. 2012;(1):27–35. (In Russ.) https://doi.org/10.14412/2074-2711-2012-358.

2. Parfenov V.A. Committee on Back Pain. Opinion Leader. 2019;(6):20–22. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=44131309.

3. Dieleman J.L., Cao J., Chapin A., Chen C., Li Z., Liu A. et al. US Health Care Spending by Payer and Health Condition, 1996–2016. JAMA. 2020;323(9):863–884. https://doi.org/10.1001/jama.2020.0734.

4. Zhivolupov S.A., Samartsev I.N., Yakovlev E.V. Pain syndromes in clinical practice of a neurologist: pathophysiology and principles of pharmacotherapy. Clinical Pharmacology and Therapy. 2017;(5):10–18. (In Russ.) Available at: https://clinpharm-journal.ru/articles/2017-5/bolevye-sindromy-v-klinicheskoj-praktike-vracha-nevrologa-patofiziologiya-i-printsipy-farmakoterapii/?ysclid=l8xhk9mzor505085980.

5. Yakovlev E.V., Leontiev O.V., Zhivolupov S.A., Gnevyshev E.N., Smirnov A.A., Zhivolupova Y.A., Samartcev I.N. Comparative characteristic of clinical efficacy of the original drug Movalis and its generic Amelotex in the treatment of non-specific lumbar pain. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;(7):56–62. (In Russ.) https://doi.org/10.17116/jnevro202012007156.

6. Yakovlev E.V., Gnevyshev E.N., Zhivolupov S.A., Smirnov A.A., Zhivolupova Yu.A., Eriskovskaya A.I., Ovsepyan A.L. Evaluation of the therapeutic efficacy of original and generic meloxicam in the treatment of acute neck pain. Meditsinskiy Sovet. 2021;(21):25–33. (In Russ.) https://doi.org/10.21518/2079-701X-2021-21-1-25-33.

7. Phillips W.J., Currier B.L. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg. 2004;12(4):221–233. https://doi.org/10.5435/00124635-200407000-00003.

8. Karateev A.E., Nasonov E.L., Yakhno N.N., Ivashkin V.T., Chichasova N.V., Alekseeva L.I. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Sovremennaya Revmatologiya. 2015;(1):4–23. (In Russ.) https://doi.org/10.14412/1996-7012-2015-1-4-23.

9. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594–606. https://doi.org/10.1053/gast.2001.21907.

10. Dawood M.Y. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428–441. https://doi.org/10.1097/01.AOG.0000230214.26638.0c.

11. Wang R., Bathon J.M., Ward M.M. Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis. Arthritis Rheumatol. 2020;72(4):518–528. https://doi.org/10.1002/art.41164.

12. Shekelle P.G., Newberry S.J., FitzGerald J.D., Motala A., O’Hanlon C.E., Tariq A. et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(1):37–51. https://doi.org/10.7326/M16-0461.

13. Oyler D.R., Parli S.E., Bernard A.C., Chang P.K., Procter L.D., Harned M.E. Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options. J Trauma Acute Care Surg. 2015;79(3):475–483. https://doi.org/10.1097/TA.0000000000000755.

14. Vellani V., Moschetti G., Franchi S., Giacomoni C., Sacerdote P., Amodeo G. Effects of NSAIDs on the Release of Calcitonin Gene-Related Peptide and Prostaglandin E2 from Rat Trigeminal Ganglia. Mediators Inflamm. 2017;2017:9547056. https://doi.org/10.1155/2017/9547056.

15. Hing E., Hall M.J., Ashman J.J., Xu J. National Hospital Ambulatory Medical Care Survey: 2007 Outpatient Department Summary. Natl Health Stat Report. 2010;(28):1–32. Available at: https://pubmed.ncbi.nlm.nih.gov/20942378.

16. Musu M., Finco G., Antonucci R., Polati E., Sanna D.,Evangelista M. et al. Acute nephrotoxicity of NSAID from the foetus to the adult. Eur Rev Med Pharmacol Sci. 2011;15(12):1461–1472. Available at: https://pubmed.ncbi.nlm.nih.gov/22288307.

17. Pai A. Keeping kidneys safe: the pharmacist’s role in NSAID avoidance in high-risk patients. J Am Pharm Assoc (2003). 2015;55(1):e15–е25. https://doi.org/10.1331/JAPhA.2015.15506.

18. Davis A., Registrar G. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016;66(645):172–173. https://doi.org/10.3399/bjgp16X684433.

19. Ghlichloo I., Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547742.

20. Sostres C., Gargallo C.J., Arroyo M.T., Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121–132. https://doi.org/10.1016/j.bpg.2009.11.005.

21. Kasciuškevičiūtė S., Gumbrevičius G., Vendzelytė A., Ščiupokas A., Petrikonis K., Kaduševičius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. Medicina (Kaunas). 2018;54(2):30. https://doi.org/10.3390/medicina54020030.

22. Rothenberg R.J., Holcomb J.P.Jr. Guidelines for Monitoring of NSAIDS: Who Listened? J Clin Rheumatol. 2000;6(5):258–265. https://doi.org/10.1097/00124743-200010000-00005.

23. Thomas D., Ali Z., Zachariah S., Sundararaj K.G.S., Van Cuyk M., Cooper J.C. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Am J Cardiovasc Drugs. 2017;17(5):343–346. https://doi.org/10.1007/s40256-017-0223-6.

24. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847. https://doi.org/10.18433/j3vw2f.

25. Talley N.J., Evans J.M., Fleming K.C., Harmsen W.S., Zinsmeister A.R., Melton L.J. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 2005;40(6):1345–1350. https://doi.org/10.1007/BF02065549.

26. Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West – a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26(2):142–154. https://doi.org/10.3350/cmh.2019.1003.

27. Sriuttha P., Sirichanchuen B., Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. Int J Hepatol. 2018;2018:5253623. https://doi.org/10.1155/2018/5253623.

28. Pereira C.M.C., Júnior G.J.D., Lima J.V.D.N., Alves Lemos S.I., da Rocha Rodrigues L., Dos Santos Ferreira J. et al. Phosphatidylinositol 3-kinase gamma participates in nimesulide-induced hepatic damage. J Pharm Pharmacol. 2021;73(4):496–504. https://doi.org/10.1093/jpp/rgaa049.

29. Kwon J., Kim S., Yoo H., Lee E. Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis. PLoS ONE. 2019;14(1):e0209264. https://doi.org/10.1371/journal.pone.0209264.

30. Bessone F., Hernandez N., Mendizabal M., Ridruejo T., Gualano G., Fassio E. et al. Serious liver injury induced by Nimesulide: an international collaborative study. Arch Toxicol. 2021;95(4):1475–1487. https://doi.org/10.1007/s00204-021-03000-8.

31. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S. https://doi.org/10.1016/s0002-9343(99)00113-8.

32. Xu Y., Li W., Han Y., Liu H., Zhang S., Yan J. et al. Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021;338:109425. https://doi.org/10.1016/j.cbi.2021.109425.

33. Rotunno R., Oppo I., Saetta G., Aveta P., Bruno S. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis. 2018;88(2):950. https://doi.org/10.4081/monaldi.2018.950.

34. Schink T., Kollhorst B., Varas C., Arfe A., Herings R., Lucchi S. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS ONE. 2018;13(9):e0203362. https://doi.org/10.1371/journal.pone.0203362.

35. Schafer A.I. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106(5B):25S–36S. https://doi.org/10.1016/s0002-9343(99)00114-x.

36. Berkes E.A. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003;24(2):137–148. https://doi.org/10.1385/CRIAI:24:2:137.

37. Terzioğlu K., Sancar Ö., Ekerbiçer H.Ç., Öztürk R.T., Epöztürk K. Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity. Asia Pac Allergy. 2020;10(3):e29. https://doi.org/10.5415/apallergy.2020.10.e29.

38. Szczeklik A. Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy. 1987;59(5):113–118. Available at: https://pubmed.ncbi.nlm.nih.gov/3318575/.

39. Cantarutti A., Franchi M., Rea F., Merlino L., Corrao G. Use of Nimesulide During Early Pregnancy and the Risk of Congenital Malformations: A Population-Based Study from Italy. Adv Ther. 2018;35(7):981–992. https://doi.org/10.1007/s12325-018-0735-8.

40. Bronstein A.C., Spyker D.A., Cantilena L.R. Jr, Green J.L., Rumack B.H., Giffin S.L. 2009 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila). 2010;48(10):979–1178. https://doi.org/10.3109/15563650.2010.543906.

41. Van der Hooft C.S., Dieleman J.P., Siemes C., Aarnoudse A.-J., Verhamme K., Stricker B., Sturkenboom M. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17(4):365–371. https://doi.org/10.1002/pds.1565.

42. Dyadyk A.I., Kugler T.E. Side effects of nonsteroidal anti-inflammatory drugs. Consilium Medicum. 2017;(12):94–99. (In Russ.) Available at: https://journals.eco-vector.com/2075-1753/article/view/94951.

43. Parfenov V.A., Yakhno N.N., Davydov O.S., Kukushkin M.L., Churyukanov M.V., Golovacheva V.A. et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics. 2019;(S1):7–16. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2S-7-16.

44. Agasarov L.G., Kuzmina I.V., Chigarev A.A., Marianovsky A.A. Clinical manifestations, pathogenesis and correction of dorsopathies. Journal of New Medical Technologies. 2015;(1):1–6. (In Russ.) Available at: https://vnmt.ru/Bulletin/E2015-1/5071.pdf.

45. Samartsev I.N., Zhivolupov S.A., Nazhmudinov R.Z., Yakovlev E.V. Study CAMELLIA: Comparative evaluation of safety and efficacy of aceclofenac and meloxicam short-term use in patients with vertebrogenic dorsalgia. Effective Pharmacotherapy. 2018;(20):38–49. (In Russ.) Available at: https://umedp.ru/upload/iblock/b50/Aertal.pdf.

46. Vetrova T.V. The role of applied relaxation techniques in the complex psychological correction of anxiety. In: Psychophysiological and medico-social aspects of applied scientific research. St Petersburg; 2022. 42 р. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=48724065.